What was intent behind the MDCG guidance for Biological Equivalence and how did it help?

Equivalence started getting noticed around 2007 and 2008 with some particular device failures. Back then, there was a much lighter approach to biological equivalence. From that time, they determined that they want materials for implants to be the same – not just similar or lower risk.


 

Related Videos

Video FAQ

What are the timelines looking like for an MDR review?

Video FAQ

Do all residual risks identified need to be listed in your IFU and SSCP?

Video FAQ

As a manufacturer, why should we bother to figure out how the MDR and IVDR will be interpreted by the NB's?
Explore All Resources

We are passionate about your success. Tell us more about your needs so we can help.

Book a Consultation

GLOBAL BOTTOM CTA INSTRUCTIONS:

To display custom copy instead of global copy in this section, please go to Show Global Content for Bottom CTA? toggle in the "Contents" tab to the left, toggle it off, save, and then REFRESH the page editor, the custom text will then show up and ready to be edited.

Turning the global content back on will be the same process, go to the toggle and toggle it back on, save and refresh!